PDF(Pubmed)
Abstract：
Cell-free DNA (cfDNA) has long been established as a useful diagnostic and prognostic tool in a variety of clinical settings, ranging from infectious to cardiovascular and neoplastic diseases. However, non-neoplastic diseases can act as confounders impacting on the amount of cfDNA shed in bloodstream and on technical feasibility of tumour derived free circulating nucleic acids selecting patients with cancer. Here, we investigated the potential impact of other pathological processes in the clinical stratification of 637 FIT+ patients. A single and multiple logistic regression yielded similar results. Crude sensitivity was 75.9% versus adjusted sensitivity of 74.1%, relative risk 0.9761 (0.8516 to 1.1188), risk difference 0.0181 (-0.0835 to 0.1199) and OR 0.9079 (0.5264 to 1.5658). Potential confounding effect from other source of cfDNA plays a pivotal role in the clinical stratification of FIT+ patients.
摘要：
长期以来，无细胞DNA（cfDNA）已被确立为各种临床环境中有用的诊断和预后工具。从传染病到心血管和肿瘤疾病。然而,非肿瘤性疾病可以作为混杂因素，影响血液中cfDNA的脱落量以及肿瘤来源的游离循环核酸选择癌症患者的技术可行性。这里,我们调查了其他病理过程对637例FIT+患者临床分层的潜在影响.单一和多元逻辑回归产生了类似的结果。粗灵敏度为75.9%，调整灵敏度为74.1%，相对风险0.9761（0.8516至1.1188），风险差异0.0181（-0.0835至0.1199）和OR0.9079（0.5264至1.5658）。来自其他cfDNA来源的潜在混杂效应在FIT+患者的临床分层中起关键作用。
